BTC 
ETH 
BNB 
XRP 
SOL 
TRX Halozyme shares up 80% this year, rivaling Merck and hitting new highs
Investor's Business Daily reports that Halozyme shares are up 80% this year and are hitting new highs while rivaling Merck. The post says Halozyme makes technologies that allow drugs delivered through intravenous infusion to instead be given with under-the-skin shots.
Why “Unverified”
- Reported by Investor's Business Daily alone, with no second source or primary confirmation yet
1 independent source group across 1 post · evidence score 52/100. How labels work
What the sources claim
-
Halozyme stock is up 80% this year.
“How Halozyme, Up 80% This Year, Is Rivaling Merck And Hitting New Highs”
Investor's Business Daily -
Halozyme is hitting new highs.
“Is Rivaling Merck And Hitting New Highs”
Investor's Business Daily -
Halozyme makes technologies that allow IV-infused drugs to be given as under-the-skin shots.
“Halozyme makes technologies that allow drugs delivered through intravenous infusion, or IV, to instead be given with under-the-skin shots”
Investor's Business Daily
Sources
More in Stocks & Indices
Summary and claims extracted by AI with prompt analyze-story@5 on 2026-10-23 12:10 UTC. Labels are computed from the sources, not by the model.